Search results
Kansas sues Pfizer over COVID vaccine for what Kris Kobach calls 'misleading marketing'
Gannett via AOL· 2 days agoKansas Attorney General Kris Kobach is suing Pfizer over its COVID-19 vaccine, alleging the company...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Raleigh Capital Management Inc. Sells 2,270 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 3 days agoRaleigh Capital Management Inc. cut its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure ...
Kansas AG Kris Kobach accuses Pfizer of misleading vaccine marketing in lawsuit
Kansas Reflector via Yahoo News· 2 days agoTOPEKA — Attorney General Kris Kobach filed a civil lawsuit Monday against pharmaceutical company ...
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit By Reuters
Investing.com· 2 days agoIn a lawsuit filed in the District Court of Thomas County, the state said the New York-based...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 6 days agoPfizer disclosed on May 7 that a child participating in another...
Wahed Invest LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoWahed Invest LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 8.6% during the 4th quarter, according to its most recent disclosure with the Securities ...
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 5 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Palantir, Oracle, Pfizer CEOs Lobby US Senators on Israel, Hostages
Bloomberg· 1 day agoHave a confidential tip for our reporters? Chief executives from major companies including Palantir...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 6 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...